Experts unpack CAPITELLO‑291 survival data, guiding post‑CDK4/6 treatment choices with capivasertib, biomarkers, and evolving targeted options.
Capivasertib and Fulvestrant for Patients With HR+/HER2− Advanced Breast Cancer: Final Overall Survival Results From the Phase 3 CAPItello-291 Trial
Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, reviews the rationale for capivasertib in hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, noting phosphatidylinositol 3-kinase (PI3K)/AKT pathway alterations in nearly half of patients, activation through PIK3CA or AKT alterations or PTEN loss, and guideline recommendations for capivasertib plus fulvestrant in altered disease after endocrine progression.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Significant is the Approval of Daraxonrasib in Pancreatic Cancer?
2
FDA Approves Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
3
Where Do CELMoDs Fit With CAR T Cells and Bispecifics in Multiple Myeloma?
4
Biomarker-Independent ADC Rina-S Advances to Phase 3 in Endometrial Cancer
5